claim
Posted by admin
•
October 03, 2026 at 04:02 PM
The promotion of oral vancomycin without comprehensive long-term safety data poses significant risks to patients with primary sclerosing cholangitis.
Vote to see results
Responses & Discussion
Log in to add your response to this statement
Log InNo responses yet. Be the first to share your perspective!